CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities:
Net (loss) income	$ (12,584)	$ 102,210
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation	1,518	1,990
Warrant liability revaluation gain	(116)	(6,983)
Future tranche right liability revaluation gain		(118,803)
Issuance of common stock for services rendered	66	130
Accretion of discounts on short-term investments		(1)
Depreciation and amortization expense	11	17
Deferred tax benefit	(6,039)
Changes in operating assets and liabilities, net of effects from Acquisition:
Accounts receivable	(49)
Prepaid expenses and other assets	806	1,930
Accounts payable, accrued expenses, and other liabilities	4,954	(1,040)
Other	142	5
Net cash used in operating activities	(11,291)	(20,545)
Cash Flows from Investing Activities:
Cash acquired in acquisition of Aceragen	5,482
Proceeds from maturity of available-for-sale securities		4,500
Net cash provided by investing activities	5,482	4,500
Cash Flows from Financing Activities:
Proceeds from common stock financings, net		19,534
Proceeds from employee stock purchases	43	48
Proceeds from exercise of common stock options and warrants	16	271
Payments on seller-financed purchases		(435)
Net cash provided by financing activities	59	19,418
Net (decrease) increase in cash and cash equivalents	(5,750)	3,373
Cash and cash equivalent, beginning of period	32,545	33,229
Cash and cash equivalents, end of period	26,795	36,602
Supplemental disclosure of cash flow information:
Cash paid for interest		$ 5
Supplemental disclosure of non-cash financing and investing activities:
Offering costs in accounts payable and accrued expenses	$ 15